<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6440">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03023085</url>
  </required_header>
  <id_info>
    <org_study_id>BLI4700-201</org_study_id>
    <nct_id>NCT03023085</nct_id>
  </id_info>
  <brief_title>A Pilot Evaluation of BLI4700 Bowel Preparation in Adult Subjects</brief_title>
  <official_title>A Pilot Evaluation of BLI4700 Bowel Preparation in Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Braintree Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Braintree Laboratories</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and efficacy of BLI4700 as a bowel
      preparation prior to colonoscopy in adult patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>% of subjects with successful bowel preparation</measure>
    <time_frame>Day of colonoscopy</time_frame>
    <description>% of subjects with successful bowel preparation rated by blinded colonoscopist on a 4 point scale (1=poor to 4 = excellent)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Colonoscopy</condition>
  <arm_group>
    <arm_group_label>BLI4700</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BLI4700 Bowel Preparation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BLI4700</intervention_name>
    <description>BLI4700 bowel preparation</description>
    <arm_group_label>BLI4700</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Male or female outpatients who are undergoing colonoscopy for a routinely accepted
             indication.

          2. Have previously had a colonoscopy performed

          3. At least 18 years of age

          4. Subjects must be scheduled for a morning colonoscopy (prior to 12:00PM)

          5. If female, and of child-bearing potential, is using an acceptable form of birth
             control.

          6. Negative urine pregnancy test at screening, if applicable

          7. In the Investigator's judgment, subject is mentally competent to provide informed
             consent to participate in the study

        Key Exclusion Criteria:

          1. Subjects with known or suspected ileus, severe ulcerative colitis, gastrointestinal
             obstruction, gastric retention, bowel perforation, toxic colitis or megacolon.

          2. Subjects who had previous significant gastrointestinal surgeries.

          3. Subjects with uncontrolled pre-existing electrolyte abnormalities, or those with
             clinically significant electrolyte abnormalities based on Visit 1 laboratory results.

          4. Subjects with a prior history of renal, liver or cardiac insufficiency

          5. Subjects with impaired consciousness that predisposes them to pulmonary aspiration.

          6. Subjects undergoing colonoscopy for foreign body removal and/or decompression.

          7. Subjects who are pregnant or lactating, or intending to become pregnant during the
             study.

          8. Subjects of childbearing potential who refuse a pregnancy test.

          9. Subjects allergic to any preparation components.

         10. Subjects who, in the opinion of the Investigator, should not be included in the study
             for any reason, including inability to follow study procedures.

         11. Subjects who have participated in an investigational surgical, drug, or device study
             within the past 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John McGowan, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Braintree Laboratories, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John McGowan, MPH</last_name>
    <phone>781-843-2202</phone>
    <email>jmcgowan@braintreelabs.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Braintree Research Site 1</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 13, 2017</lastchanged_date>
  <firstreceived_date>January 13, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
